BioIntelliSense, Medically Home Collaborate on Home Hospital Care

BioIntelliSense Inc. is joining forces with Medically Home Group Inc. to improve home hospital care for seriously ill patients.

The partnership aims to help home healthcare clinicians better prioritize care, allocate resources, and advance clinical workflow in treating and caring for patients with complex or high-risk conditions. Physicians and nurses will have access to the BioIntelliSense medical grade BioButton wearable devices. 
 
“Our strategic collaboration with Medically Home advances a shared vision for a scalable and patient-centric model of healthcare delivery,” BioIntelliSense Founder/CEO James Mault, M.D., said. “High frequency vital sign trending data, combined with algorithmic-based alerting, provides clinicians with greater insights for patient care from in-hospital to home. This represents a significant advancement in admitting to home with confidence and bringing medical grade continuous monitoring to the lowest cost care setting.”
 
The rechargeable multi-parameter BioButton wearable devices passively capture clinically validated vital signs of heart rate at rest, respiratory rate at rest and skin temperature, along with a broad range of physiologic biometrics, including activity levels, sleep tracking, body position and gait analysis. The BioCloud data analytics and algorithmic-based alerting enable actionable clinical triage and proactive clinical intervention through potential earlier detection of adverse trends.
 
The Medically Home model directly addresses the growing need for increased health system capacity and resiliency, while meeting the needs and preferences of patients, who often desire to be cared for in the comfort and convenience of their home. With the comprehensive Medically Home and BioIntelliSense solution, patients with conditions across a broad spectrum of severity, complexity, and risk can continue to be cared for safely at home with clinical accuracy, reducing the necessity for traditional building-centric care.
 
“BioIntelliSense provides a scalable medical-grade solution that allows for passive vital sign data collection from the home, dramatically reducing the cost and complexity of deploying traditional remote patient monitoring programs with improved patient experience,” Medically Home Chief Medical Officer Pippa Shulman, D.O., MPH, said. “As hospital capacity pressure mounts, this strategic collaboration further accelerates Medically Home’s platform reach and growing ecosystem of health systems and payers nationwide.”
 
BioIntelliSense’s medical-grade Data-as-a-Service (DaaS) platform seamlessly captures multi-parameter vital signs, physiological biometrics and symptomatic events. The medical-grade BioButton wearable device makes remote monitoring and early detection simple. Through the platform’s advanced analytics, clinicians have access to high-resolution patient trending and reporting to enable medical grade remote care from in-hospital to home.
 
Medically Home operates a decentralized care model for patients with serious, complex, or high-risk illnesses in partnership with health systems to safely care for their patients at home, across the care continuum, including hospital-level care. Medically Home provides health systems with clinical protocols, reimbursement model, platform technology, and fulfillment of all clinical services required in the home through partners.